Immunotherapy Trials in Head and Neck Cancer
This video reviews ongoing trials testing immunotherapy for patients with head and neck cancer.
In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses two ongoing trials testing immunotherapy in different settings for patients with head and neck cancer.
The first, a phase III trial, is testing standard of care vs pembrolizumab or chemotherapy plus pembrolizumab in patients with metastatic head and neck cancer.
The second trial is studying the efficacy of pembrolizumab prior to salvage surgery in patients whose disease has recurred after already having received definitive chemoradiation.
Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy
April 28th 2024Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.
Prognostic Factors Linked With Poor Locoregional Control in Tongue Cancer
March 5th 2024Patients with factors such as lymphovascular space invasion or positive glossectomy specimen margins may be considered for adjuvant radiotherapy to optimize disease control of tongue squamous cell carcinoma.
